The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 22, 2024
Filed:
Jun. 14, 2019
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Université Paul Sabatier Toulouse Iii, Toulouse, FR;
University College London, London, GB;
Centre Hospitalier Universitaire DE Toulouse, Toulouse, FR;
Université DE Caen Normandie, Caen, FR;
Centre Hospitalier Régional Universitaire DE Caen, Caen, FR;
Marie-Pierre Gratacap, Toulouse, FR;
Jean Darcourt, Toulouse, FR;
Bart Vanhaesebroeck, London, GB;
Gaëtan Chicanne, Toulouse, FR;
Bernard Payrastre, Toulouse, FR;
Vincent Larrue, Toulouse, FR;
Romain Solinhac, Toulouse, FR;
Aude Jaffre, Toulouse, FR;
Denis Vivien, Caen, FR;
Typhaine Anquetil, Toulouse, FR;
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Paris, FR;
UNIVERSITE PAUL SABATIER TOULOUSE III, Toulouse, FR;
UNIVERSITY COLLEGE LONDON, London, GB;
CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, Toulouse, FR;
UNIVERSITE DE CAEN NORMANDIE, Caen, FR;
CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE CAEN, Caen, FR;
Abstract
Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2β reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation. Accordingly, the present invention relates to a method for the preservation of vascular endothelial cell barrier integrity in a patient in need thereof comprising administering to the subject a therapeutically effective amount of a PI3KC2β inhibitor.